MPN-140 The Role of 18F-FDG PET/CT Scan in Adult Langerhans Cell Histiocytosis: A Single-Center Experience

• Published in: Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2023-09, Vol.23, p.S384-S385
• Main Authors: Erdem, Simge, Çetin, Okan, Kıran, Murat Yılmaz, Işık, Emine Göknur, Beyaz, Şengül, Yeğen, Gülçin, Oluk, Beyaz, Sakcı, Elif, Taghiyeva, Nigar, Hindilerden, İpek Yönal, Yenerel, Mustafa Nuri, Nalçacı, Meliha, Beşışık, Sevgi Kalayoğlu
• Format: Article
• Language: English
• Subjects: 18F-fluorodeoxyglucose; glycometabolic activity; Langerhans cell histiocytosis; LCH; MPN
• ISSN: 2152-2650; 2152-2669
• DOI: 10.1016/S2152-2650(23)01223-5

This study aimed to evaluate the potential role of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT scan) in adult patients with Langerhans cell histiocytosis (LCH) by integrating glycometabolic activity and anatomical images. Patients diagnosed with LCH who underwent an 18F-FDG PET/CT scan between 1997 and 2022 were included in the study. Data were collected electronically, and statistical analyses were performed using SPSS 25.0. The results were presented as mean±standard deviation (SD), median±interquartile range (IQR), or frequency (%). The data of 43 patients were reviewed, with a mean age at diagnosis of 31 years (range: 2–63 years) and a male-to-female predominance of 2.9:1. Of the patients, 34 underwent PET/CT scans, with 7 patients having FDG-negative scans. Among the patients, 9 had more than 10 FDG-positive lesions, and 2 had multiple lung lesions. Bone lesions were the most commonly encountered (82%). The mean maximum standardized uptake value (SUVmax) among involved organs were as follows: bone 7.35, lung 5.33, lymph node 5.56, brain 36.35, skin 10.44, and thyroid 16. This study provides valuable insights into the use of 18F-FDG PET/CT imaging in adult LCH. The whole-body imaging capability of PET/CT scans can help identify risk organ involvement and guide treatment decisions. However, it should be noted that our study did not prospectively schedule data for response monitoring and it is premature to draw conclusions based on SUVmax ratios. Further research is needed to validate the potential of 18F-FDG PET/CT in monitoring treatment response in adult LCH patients.